The PharmacoEpi and Risk Management (PRM) Newsletter

Welcome to the April 2014 edition of the PRM Newsletter.

We discuss the considerations of developing biosimilars, using the soon-to-be out-of-patent Avastin (bevacizumab) as an example. Our pharmacovigilance hot topic this month pertains to the ADR database: PROTECT.

There are, as always, a few more snippets of news to keep you informed and entertained on your commute home. ENJOY!

Should we be missing anything – or if you’d like to engage us in conversation – please feel free to follow the instructions for submitting authors (at the above button), or write to me, Naomi Boxall, at nboxall@mapigroup.com. You can also follow the newsletter on twitter: @prmnewsletter.

     
  Lead Article:
Avastin (bevacizumab) Biosimilar Development Considerations
 
   
  Hot Topic:
The PROTECT ADR Database
 
     
SEARCH